Matrix stiffness-related extracellular matrix signatures and the DYNLL1 protein promote hepatocellular carcinoma progression through the Wnt/β-catenin pathway.

ABSTRACT:

Background

In hepatocellular carcinoma (HCC) treatment, first-line targeted therapy in combination with immune checkpoint inhibitors (ICIs) has improved patient prognosis, but the 5-year survival rate is far from satisfactory. Studies have shown that the extracellular matrix (ECM) is an essential part of the tumour microenvironment (TME) and participates in the progression of malignant tumours. ECM remodelling can enhance matrix stiffness in cirrhosis patients, induce an immunosuppressive microenvironment network, and affect the efficacy of targeted therapies and ICIs for treating HCC. However, the exact mechanism is still unclear.

Methods

We downloaded data from public databases, selected differentially expressed ECM proteins associated with matrix stiffness, constructed an

SUBMITTER: Shen Y 

PROVIDER: S-EPMC11440708 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature